MCID: PRG106
MIFTS: 40

Progressive Muscular Dystrophy malady

Categories: Rare diseases, Muscle diseases, Genetic diseases, Neuronal diseases, Cardiovascular diseases

Aliases & Classifications for Progressive Muscular Dystrophy

Aliases & Descriptions for Progressive Muscular Dystrophy:

Name: Progressive Muscular Dystrophy 50
Muscular Dystrophy 69

Classifications:



Summaries for Progressive Muscular Dystrophy

MalaCards based summary : Progressive Muscular Dystrophy, also known as muscular dystrophy, is related to myopathy, x-linked, with postural muscle atrophy and facioscapulohumeral muscular dystrophy 1, and has symptoms including back pain, muscle cramp and myoclonus. An important gene associated with Progressive Muscular Dystrophy is SGCA (Sarcoglycan Alpha), and among its related pathways/superpathways are Mannose type O-glycan biosynthesis and Muscular Dystrophies and Dystrophin-Glycoprotein Complex. The drugs Ramipril and Carvedilol have been mentioned in the context of this disorder. Affiliated tissues include heart and bone, and related phenotypes are cardiovascular system and growth/size/body region

Related Diseases for Progressive Muscular Dystrophy

Diseases in the Muscular Dystrophy family:

Muscular Dystrophy, Congenital Muscular Dystrophy, Congenital, 1b
Congenital Muscular Dystrophy Due to Lmna Mutation Lama2-Related Muscular Dystrophy
Congenital Muscular Dystrophy Due to Dystroglycanopathy Congenital Muscular Dystrophy Type 1a
Progressive Muscular Dystrophy

Diseases related to Progressive Muscular Dystrophy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 58)
id Related Disease Score Top Affiliating Genes
1 myopathy, x-linked, with postural muscle atrophy 10.9
2 facioscapulohumeral muscular dystrophy 1 10.9
3 oculopharyngeal muscular dystrophy 10.9
4 duchenne muscular dystrophy 10.9
5 epidermolysis bullosa simplex with muscular dystrophy 10.8
6 muscular dystrophy 10.5
7 eif2b1-related childhood ataxia with central nervous system hypomyelination/vanishing white matter 10.2 DMD SGCA
8 sudden infant death with dysgenesis of the testes syndrome 10.2 DMD SGCA
9 pancreatic agenesis 1 10.2 DMD SGCA
10 sdhc-related paraganglioma and gastric stromal sarcoma 10.2 DMD SGCA
11 glomerulonephritis 10.1 DMD MB
12 hiatus hernia 10.1 DMD NOS1
13 soft palate cancer 10.1 DMD MB
14 congenital myopathy 10.1 DMD FHL1
15 idiopathic juvenile osteoporosis 10.1 MB NPPA
16 nonsyndromic hearing loss and deafness, mitochondrial 10.0 DMD FHL1
17 asthma-related traits 6 10.0 FKRP SGCA
18 vestibulocochlear nerve disease 10.0 DMD NOS1
19 autosomal recessive limb-girdle muscular dystrophy type 2x 10.0 FKRP SGCA
20 acute lymphoblastic leukemia, childhood 10.0 MB NPPA
21 autosomal recessive limb-girdle muscular dystrophy type 2w 10.0 FKRP SGCA
22 cardiomyopathy, dilated, 1aa, with or without lvnc 10.0 DMD FKRP
23 spinocerebellar ataxia 11 10.0 FKRP SGCA
24 aminoaciduria 10.0
25 immunodeficiency 34, mycobacteriosis, x-linked 10.0 DMD MB NOS1 SGCA
26 alk-positive large b-cell lymphoma 10.0 FKRP POMT2
27 nephronophthisis 2, infantile 10.0 FKRP POMT2
28 hydroa vacciniforme-like lymphoma 10.0 FKRP POMT2
29 deafness, autosomal recessive 18b 10.0 FKRP POMT2
30 muscular dystrophy, rigid spine, 1 10.0 DMD FHL1
31 asphyxiating thoracic dystrophy 9.9 FKRP POMT2
32 myopathy, distal, with anterior tibial onset 9.9 DMD FKRP SGCA
33 autosomal recessive limb-girdle muscular dystrophy type 2h 9.9 DMD FKRP SGCA
34 gastric dilatation 9.8
35 dermatofibrosarcoma protuberans 9.8 DMD FKRP POMT2
36 cone-rod dystrophy, prph2-related 9.8 DMD FKRP POMT2
37 glycogen storage disease 0, muscle 9.8 DMD FKRP POMT2
38 muscular dystrophy, limb-girdle, type 1b 9.8 DMD FKRP POMT2
39 hypereosinophilic syndrome, idiopathic, resistant to imatinib 9.8 FKRP SGCA
40 thrombocytopenia, x-linked 9.8 DMD FKRP NOS1 SGCA
41 cerebral angioma 9.8 DMD FKRP MB SGCA
42 myasthenia gravis, limb-girdle 9.7 DMD FKRP POMT2 SGCA
43 autosomal dominant nonsyndromic deafness 9.7 DMD FKRP POMT2 SGCA
44 central corneal ulcer 9.7 DMD FKRP POMT2 SGCA
45 neuronitis 9.7
46 multiple myeloma 9.7
47 proximal spinal muscular atrophy 9.7
48 pentosuria 9.7
49 congestive heart failure 9.7
50 spinal muscular atrophy 9.7

Comorbidity relations with Progressive Muscular Dystrophy via Phenotypic Disease Network (PDN):


Acute Cystitis

Graphical network of the top 20 diseases related to Progressive Muscular Dystrophy:



Diseases related to Progressive Muscular Dystrophy

Symptoms & Phenotypes for Progressive Muscular Dystrophy

UMLS symptoms related to Progressive Muscular Dystrophy:


back pain, muscle cramp, myoclonus, sciatica, torticollis

MGI Mouse Phenotypes related to Progressive Muscular Dystrophy:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.92 CTGF DMD FHL1 MB MTAP NOS1
2 growth/size/body region MP:0005378 9.8 MB NOS1 POMT2 CTGF DMD FHL1
3 homeostasis/metabolism MP:0005376 9.76 CTGF DMD FHL1 FKRP MB NOS1
4 muscle MP:0005369 9.5 MB NOS1 NPPA SGCA DMD FHL1
5 respiratory system MP:0005388 9.02 CTGF DMD MB MTAP NOS1

Drugs & Therapeutics for Progressive Muscular Dystrophy

Drugs for Progressive Muscular Dystrophy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 250)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ramipril Approved Phase 4 87333-19-5 5362129
2
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
3
Alendronate Approved Phase 4 121268-17-5, 66376-36-1 2088
4
Tadalafil Approved, Investigational Phase 4,Phase 3,Phase 1,Early Phase 1 171596-29-5 110635
5
protease inhibitors Phase 4,Phase 3,Phase 2
6 Adrenergic Agents Phase 4,Phase 3
7 Adrenergic Antagonists Phase 4
8 Adrenergic alpha-1 Receptor Antagonists Phase 4
9 Adrenergic alpha-Antagonists Phase 4
10 Neurotransmitter Agents Phase 4,Phase 2,Phase 3
11 Adrenergic beta-Antagonists Phase 4
12 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2
13 Vasodilator Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
14 Angiotensin-Converting Enzyme Inhibitors Phase 4,Phase 3,Phase 2
15 Vitamins Phase 4,Phase 2,Phase 3
16 Antihypertensive Agents Phase 4,Phase 3,Phase 2
17 Bone Density Conservation Agents Phase 4,Phase 3,Phase 1
18 Calcium, Dietary Phase 4,Phase 3
19 vitamin d Phase 4
20 Risedronate Sodium Phase 4 115436-72-1
21 Diphosphonates Phase 4,Phase 3
22 Anti-Bacterial Agents Phase 4,Phase 2,Phase 1
23 Phosphodiesterase 5 Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
24 Phosphodiesterase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
25 Antibiotics, Antitubercular Phase 4
26
Dopamine Approved Phase 2, Phase 3 51-61-6, 62-31-7 681
27
Lamotrigine Approved, Investigational Phase 3 84057-84-1 3878
28
Metformin Approved Phase 3,Phase 2,Phase 1 657-24-9 14219 4091
29
Enalapril Approved, Vet_approved Phase 3 75847-73-3 5362032 40466924
30
Lisinopril Approved, Investigational Phase 2, Phase 3 83915-83-7 5362119
31
Enalaprilat Approved Phase 3 76420-72-9 6917719
32
Spironolactone Approved Phase 3 1952-01-7, 52-01-7 5833
33
Eplerenone Approved Phase 3 107724-20-9 150310 443872
34
Methylphenidate Approved, Investigational Phase 2, Phase 3 113-45-1 4158
35 Deflazacort Approved Phase 2, Phase 3, Phase 1 14484-47-0
36 Idebenone Approved, Investigational Phase 3,Phase 2 58186-27-9
37
Benzocaine Approved Phase 3 1994-09-7, 94-09-7 2337
38
Prednisone Approved, Vet_approved Phase 3,Phase 2 53-03-2 5865
39
Zoledronic acid Approved Phase 3 118072-93-8 68740
40
Nebivolol Approved, Investigational Phase 3 152520-56-4, 99200-09-6, 118457-14-0 71301
41
Vitamin C Approved, Nutraceutical Phase 2, Phase 3 50-81-7 5785 54670067
42 tannic acid Approved, Nutraceutical Phase 3
43
Dehydroepiandrosterone Approved, Nutraceutical Phase 2, Phase 3 53-43-0 9860744
44
Creatine Approved, Nutraceutical Phase 2, Phase 3 57-00-1 586
45 diuretics Phase 3,Phase 1
46 Natriuretic Agents Phase 3,Phase 1
47 Trace Elements Phase 3,Phase 2
48 Hypoglycemic Agents Phase 3,Phase 2,Phase 1
49 4-des-dimethylaminotetracycline Phase 2, Phase 3
50 Protective Agents Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 379)
id Name Status NCT ID Phase
1 The Preventive Efficacy of Carvedilol on Cardiac Dysfunction in Duchenne Muscular Dystrophy Unknown status NCT00606775 Phase 4
2 Ramipril Versus Carvedilol in Duchenne and Becker Patients Unknown status NCT00819845 Phase 4
3 Tadalafil in Becker Muscular Dystrophy Completed NCT01070511 Phase 4
4 PDE5 Inhibition to Alleviate Functional Muscle Ischemia in Becker Muscular Dystrophy Completed NCT02207283 Phase 4
5 Assessment of Response to Treatment of Osteoporosis With Oral Bisphosphonates in Patients With Muscular Dystrophy Completed NCT01882400 Phase 4
6 Stacking Exercises Aid the Decline in FVC and Sick Time Active, not recruiting NCT01999075 Phase 4
7 Effects of Sodium Nitrate on Blood Flow in Becker Muscular Dystrophy Unknown status NCT02147639 Phase 2, Phase 3
8 RAMYD Study - Evaluation of Arrhythmic Risk in Myotonic Dystrophy Unknown status NCT00127582 Phase 3
9 High-dose Prednisone in Duchenne Muscular Dystrophy Completed NCT00110669 Phase 3
10 L-citrulline and Metformin in Duchenne's Muscular Dystrophy Completed NCT01995032 Phase 3
11 A Clinical Study to Assess the Efficacy and Safety of GSK2402968 in Subjects With Duchenne Muscular Dystrophy Completed NCT01254019 Phase 3
12 Phase 2b Study of PTC124 in Duchenne/Becker Muscular Dystrophy (DMD/BMD) Completed NCT00592553 Phase 2, Phase 3
13 Myocardial Fibrosis Progression in Duchenne and Becker Muscular Dystrophy - ACE Inhibitor Therapy Trial Completed NCT02432885 Phase 3
14 Creatine and Glutamine in Steroid-Naive Duchenne Muscular Dystrophy Completed NCT00016653 Phase 2, Phase 3
15 Phase III Randomized, Double-Blind Study of Prednisone for Duchenne Muscular Dystrophy Completed NCT00004646 Phase 3
16 Phase III Study of Idebenone in Duchenne Muscular Dystrophy (DMD) Completed NCT01027884 Phase 3
17 A Multicenter Randomized Placebo-Controlled Double-Blind Study to Assess Efficacy and Safety of Glutamine and Creatine Monohydrate in Duchenne Muscular Dystrophy (DMD) Completed NCT00018109 Phase 3
18 Phase 3 Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy Completed NCT01826487 Phase 3
19 Deflazacort in Dysferlinopathies Completed NCT00527228 Phase 2, Phase 3
20 High Dose Ascorbic Acid Treatment of CMT1A Completed NCT00484510 Phase 2, Phase 3
21 Methylphenidate in Myotonic Dystrophy Type 1 Completed NCT01421992 Phase 2, Phase 3
22 Efficacy and Safety of DHEA for Myotonic Dystrophy Completed NCT00167609 Phase 2, Phase 3
23 Lamotrigine as Treatment of Myotonia Completed NCT01939561 Phase 3
24 Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of BMS-986089 in Ambulatory Boys With Duchenne Muscular Dystrophy Recruiting NCT03039686 Phase 2, Phase 3
25 A Phase III Double-blind Study With Idebenone in Patients With Duchenne Muscular Dystrophy (DMD) Taking Glucocorticoid Steroids Recruiting NCT02814019 Phase 3
26 Study of SRP-4045 and SRP-4053 in DMD Patients Recruiting NCT02500381 Phase 3
27 1 Year Open-label Extension to CZOL446H2337 Safety and Efficacy Trial of Zoledronic Acid Twice Yearly in Osteoporotic Children Treated With Glucocorticoids Recruiting NCT01197300 Phase 3
28 A Research Study of Zoledronic Acid in Children and Adolescents With Osteoporosis Recruiting NCT00799266 Phase 3
29 Sunphenon Epigallocatechin-Gallate (EGCg) in Duchenne Muscular Dystrophy Active, not recruiting NCT01183767 Phase 2, Phase 3
30 Finding the Optimum Regimen for Duchenne Muscular Dystrophy Active, not recruiting NCT01603407 Phase 3
31 Therapeutic Potential for Aldosterone Inhibition in Duchenne Muscular Dystrophy Active, not recruiting NCT02354352 Phase 3
32 Nebivolol for the Prevention of Left Ventricular Systolic Dysfunction in Patients With Duchenne Muscular Dystrophy Active, not recruiting NCT01648634 Phase 3
33 Confirmatory Study of Eteplirsen in DMD Patients Active, not recruiting NCT02255552 Phase 3
34 Treatment of Ptosis to Muscular Dystrophy Oculopharyngeal by Myoblast Autologous Graft Active, not recruiting NCT02878694 Phase 2, Phase 3
35 Continuation Protocol to Protocol BBCO-001 Active, not recruiting NCT02328482 Phase 3
36 Study of Ataluren for Previously Treated Patients With nmDBMD in Europe, Israel, Australia, and Canada Active, not recruiting NCT01557400 Phase 3
37 Phase 3 Extension Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy Active, not recruiting NCT02090959 Phase 3
38 Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Sialic Acid in Patients With GNE Myopathy (GNEM) or Hereditary Inclusion Body Myopathy (HIBM) Active, not recruiting NCT02377921 Phase 3
39 Efficacy and Tolerance of Early Launching of Nocturnal Non Invasive Active, not recruiting NCT01225614 Phase 3
40 Clinical Trial of Coenzyme Q10 and Lisinopril in Muscular Dystrophies Enrolling by invitation NCT01126697 Phase 2, Phase 3
41 Study of Ataluren for Previously Treated Patients With nmDBMD in the US Enrolling by invitation NCT01247207 Phase 3
42 Study to Evaluate the Safety and Efficacy of Ace-ER Tablets in Patients With GNE Myopathy or Hereditary Inclusion Body Myopathy Enrolling by invitation NCT02736188 Phase 3
43 Clinical Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular Dystrophy Not yet recruiting NCT02851797 Phase 3
44 Long-Term Outcomes of Ataluren in Duchenne Muscular Dystrophy Not yet recruiting NCT03179631 Phase 3
45 Phase 2b Extension Study of Ataluren (PTC124) in Duchenne/Becker Muscular Dystrophy (DMD/BMD) Terminated NCT00847379 Phase 2, Phase 3
46 A Study of Tadalafil for Duchenne Muscular Dystrophy Terminated NCT01865084 Phase 3
47 Open Label Study of GSK2402968 in Subjects With Duchenne Muscular Dystrophy Terminated NCT01480245 Phase 3
48 CoQ10 and Prednisone in Non-Ambulatory DMD Terminated NCT00308113 Phase 3
49 A Study of the Safety, Tolerability & Efficacy of Long-term Administration of Drisapersen in US & Canadian Subjects Terminated NCT01803412 Phase 3
50 Extension Study of Drisapersen in DMD Subjects Terminated NCT02636686 Phase 3

Search NIH Clinical Center for Progressive Muscular Dystrophy

Genetic Tests for Progressive Muscular Dystrophy

Anatomical Context for Progressive Muscular Dystrophy

MalaCards organs/tissues related to Progressive Muscular Dystrophy:

39
Heart, Bone

Publications for Progressive Muscular Dystrophy

Articles related to Progressive Muscular Dystrophy:

(show all 43)
id Title Authors Year
1
Progressive muscular dystrophy of heart: diagnosis easily missed by clinicians. ( 24585649 )
2014
2
Histological comparison of the smooth uterine muscle of healthy golden retriever bitches, carriers of the progressive muscular dystrophy (GRMD) gene, and GRMD-affected bitches. ( 25200710 )
2014
3
50 years ago in the Journal of Pediatrics: the use of serum creatine phosphokinase and other serum enzymes in the diagnosis of progressive muscular dystrophy. ( 24274203 )
2013
4
Angioedema in progressive muscular dystrophy: a case report. ( 22908833 )
2012
5
Mutations in LAMA2 and CAPN3 genes associated with genetic and phenotypic heterogeneities within a single consanguineous family involving both congenital and progressive muscular dystrophies. ( 20477750 )
2011
6
Myocardial strain imaging for early detection of cardiac involvement in patients with Duchenne's progressive muscular dystrophy. ( 17584199 )
2007
7
[Altered expression of myostatin gene in the progressive muscular dystrophy patients]. ( 16231730 )
2005
8
Continuous infusion propofol general anesthesia for dental treatment in patients with progressive muscular dystrophy. ( 15859443 )
2005
9
[Expression of connective tissue growth factor in progressive muscular dystrophy]. ( 16255854 )
2005
10
Peak negative myocardial velocity gradient and wall-thickening velocity during early diastole are noninvasive parameters of left ventricular diastolic function in patients with Duchenne's progressive muscular dystrophy. ( 15044864 )
2004
11
[Association between dystrophin and neuronal nitric oxide synthase in muscles of progressive muscular dystrophy]. ( 11953148 )
2002
12
Plasma levels of natriuretic peptide and echocardiographic parameters in patients with Duchenne's progressive muscular dystrophy. ( 11889527 )
2002
13
Thallium-201 single photon emission computed tomography (SPECT) in patients with duchenne's progressive muscular dystrophy: a histopathologic correlation study. ( 11216833 )
2001
14
Myocardial integrated ultrasound backscatter in patients with Duchenne's progressive muscular dystrophy. ( 11514494 )
2001
15
A 15-year-old male with progressive muscular dystrophy of the becker type and severe heart failure. ( 10967589 )
2000
16
Motor unit changes in inflammatory myopathy and progressive muscular dystrophy. ( 11142114 )
2000
17
QT dispersion in patients with Duchenne-type progressive muscular dystrophy. ( 10097228 )
1999
18
Problems and solutions in the rehabilitation of patients with progressive muscular dystrophy. ( 10370970 )
1999
19
Mosaic expression of two dystrophins in a boy with progressive muscular dystrophy. ( 9736061 )
1998
20
Expression of genes (CAPN3, SGCA, SGCB, and TTN) involved in progressive muscular dystrophies during early human development. ( 9521867 )
1998
21
Progressive muscular dystrophy in alpha-sarcoglycan-deficient mice. ( 9744877 )
1998
22
How the magnitude of clinical severity and recurrence risk affects reproductive decisions in adult males with different forms of progressive muscular dystrophy. ( 9541101 )
1998
23
Nine-year follow-up study of heart rate variability in patients with Duchenne-type progressive muscular dystrophy. ( 9704692 )
1998
24
Social adjustment in adult males affected with progressive muscular dystrophy. ( 9514580 )
1998
25
Normal expression of adhalin and merosin in ovine congenital progressive muscular dystrophy. ( 9088516 )
1997
26
Refined genetic location of the chromosome 2p-linked progressive muscular dystrophy gene. ( 9192858 )
1997
27
[Monoclonal antibodies to dystrophin in biopsy diagnosis of Duchenne and Becker progressive muscular dystrophies]. ( 8020113 )
1994
28
Expression of transforming growth factor-beta 1 and its relation to endomysial fibrosis in progressive muscular dystrophy. ( 8311110 )
1994
29
[Alteration of atrial natriuretic peptide in progressive muscular dystrophy with congestive heart failure]. ( 1424336 )
1992
30
Early onset autosomal dominant progressive muscular dystrophy presenting in childhood as a Becker phenotype--the importance of dystrophin and molecular genetic analysis. ( 1422199 )
1992
31
Dystrophin abnormality in progressive muscular dystrophy--a review article. ( 1957648 )
1991
32
Autosomal recessive distal muscular dystrophy as a new type of progressive muscular dystrophy. Seventeen cases in eight families including an autopsied case. ( 3942856 )
1986
33
Multiple myeloma occurring in association with a preexisting neuromuscular disease (progressive muscular dystrophy). A chance occurrence or a nosological entity? ( 6437121 )
1984
34
The linkage between Duchenne-type progressive muscular dystrophy and color blindness. ( 5313771 )
1970
35
Aminoaciduria in progressive muscular dystrophy. A family study. ( 6044995 )
1967
36
Acute gastric dilatation in progressive muscular dystrophy. ( 13974390 )
1963
37
Anaesthesia and post-operative complications in progressive muscular dystrophy. Tachycardia and acute gastric dilatation. ( 14001340 )
1962
38
Aminoaciduria in progressive muscular dystrophy. ( 13970673 )
1962
39
Abnormality of the long bones and progressive muscular dystrophy in a family. ( 13511301 )
1958
40
Studies in disorders of muscle. XI. The problem of pentosuria in progressive muscular dystrophy. ( 13358571 )
1956
41
Hereditary proximal spinal muscular atrophy, a clinical entity simulating progressive muscular dystrophy. ( 13301901 )
1955
42
Aminoaciduria in progressive muscular dystrophy. ( 18856429 )
1948
43
Aminoaciduria in progressive muscular dystrophy. ( 18863698 )
1948

Variations for Progressive Muscular Dystrophy

Expression for Progressive Muscular Dystrophy

Search GEO for disease gene expression data for Progressive Muscular Dystrophy.

Pathways for Progressive Muscular Dystrophy

Pathways related to Progressive Muscular Dystrophy according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 10.52 FKRP POMT2
2 10.23 DMD NOS1
3 9.53 MB NOS1

GO Terms for Progressive Muscular Dystrophy

Cellular components related to Progressive Muscular Dystrophy according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 membrane raft GO:0045121 9.33 DMD NOS1 SGCA
2 sarcolemma GO:0042383 9.26 DMD FKRP NOS1 SGCA
3 dystrophin-associated glycoprotein complex GO:0016010 8.8 DMD FKRP SGCA

Biological processes related to Progressive Muscular Dystrophy according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 response to hypoxia GO:0001666 9.63 MB NOS1 NPPA
2 regulation of cardiac conduction GO:1903779 9.48 NOS1 NPPA
3 skeletal muscle tissue regeneration GO:0043403 9.43 DMD SGCA
4 response to muscle stretch GO:0035994 9.4 DMD NPPA
5 regulation of ryanodine-sensitive calcium-release channel activity GO:0060314 9.37 DMD NOS1
6 muscle organ development GO:0007517 9.33 DMD FHL1 SGCA
7 protein O-linked mannosylation GO:0035269 9.32 FKRP POMT2
8 response to denervation involved in regulation of muscle adaptation GO:0014894 9.26 DMD SGCA
9 positive regulation of cardiac muscle contraction GO:0060452 8.96 CTGF NPPA
10 regulation of calcium ion transmembrane transport via high voltage-gated calcium channel GO:1902514 8.62 NOS1 NPPA

Sources for Progressive Muscular Dystrophy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....